TY - JOUR
T1 - Executive summary
T2 - Japanese pediatric guideline for the treatment and management of asthma (JPGL) 2020
AU - Committee for Japanese Pediatric Guideline for the Treatment and Management of Asthma
AU - The Japanese Society of Pediatric Allergy and Clinical Immunology
AU - The Japanese Society of Allergology
AU - Adachi, Yuichi
AU - Takizawa, Takumi
AU - Futamura, Masaki
AU - Fujisawa, Takao
AU - Yoshihara, Shigemi
AU - Committee members, members
AU - Shimojo, Naoki
AU - Iino, Akira
AU - Ebisawa, Mothiro
AU - Mochizuki, Hiroyuki
AU - Ohya, Yukihiro
AU - Katsunuma, Toshio
AU - Kameda, Makoto
AU - Inoue, Toshishige
AU - Fukuie, Tatsuki
AU - External committee members, committee members
AU - Iwanaga, Takashi
AU - Kuriyama, Mariko
AU - Kuroki, Haruo
AU - Sonobe, Mariko
AU - Takase, Masato
AU - Masuko, Ikuyo
AU - Collaborators,
AU - Yamaide, Fumiya
AU - Yoshida, Koichi
AU - Nagakura, Kenichi
AU - Hirai, Kota
AU - Miyaji, Yumiko
AU - Ito, Yasunori
AU - Yagi, Hisako
AU - Miura, Katsushi
AU - Horino, Satoshi
AU - Fukuda, Hironobu
AU - Yoshida, Yukinori
AU - Takahashi, Shinichi
AU - Natsume, Osamu
AU - Nagao, Mizuho
AU - Yamada, Yoshiyuki
AU - Members of systematic review team, of systematic review team
AU - Okafuji, Ikuo
AU - Yamamoto-Hanada, Kiwako
AU - Nakajima, Yoichi
AU - Tanaka, Yuya
AU - Suzuki, Shuichi
AU - Sato, Kotaro
AU - Murai, Hiroki
AU - Miura, Taro
AU - Hiraguchi, Yukiko
AU - Takaoka, Yuri
AU - Manabe, Tetsuharu
N1 - Publisher Copyright:
© 2022 Japanese Society of Allergology
PY - 2022/10
Y1 - 2022/10
N2 - This article covers the salient and updated themes of the Japanese Pediatric Guidelines for the Treatment and Management of Asthma (JPGL) 2020 published by the Japanese Society of Pediatric Allergy and Clinical Immunology. In the 2020 guidelines, five new clinical questions (CQs) have been added to address the 12 CQs regarding the treatment of childhood asthma. “Infant and preschool asthma” is diagnosed when young children (<6 years of age) have three or more episodes of clear expiratory wheezing, which continue for more than 24 h, and symptom improvement can be observed after beta-2 agonist inhalation. In children without clear improvement, diagnostic therapeutic trial for the duration of 1 month with controller treatment can be used. Since long-term management is initiated, the treatment level is adjusted based on the current control status and the management of risk factors, with the provision for holistic care. This underscores the smooth transition of pediatric patients into adult services. There are several differences between the JPGL and the guidelines of other countries. Further evidence is obtained as the utility of the newly proposed management plans should be evaluated in the Japanese population.
AB - This article covers the salient and updated themes of the Japanese Pediatric Guidelines for the Treatment and Management of Asthma (JPGL) 2020 published by the Japanese Society of Pediatric Allergy and Clinical Immunology. In the 2020 guidelines, five new clinical questions (CQs) have been added to address the 12 CQs regarding the treatment of childhood asthma. “Infant and preschool asthma” is diagnosed when young children (<6 years of age) have three or more episodes of clear expiratory wheezing, which continue for more than 24 h, and symptom improvement can be observed after beta-2 agonist inhalation. In children without clear improvement, diagnostic therapeutic trial for the duration of 1 month with controller treatment can be used. Since long-term management is initiated, the treatment level is adjusted based on the current control status and the management of risk factors, with the provision for holistic care. This underscores the smooth transition of pediatric patients into adult services. There are several differences between the JPGL and the guidelines of other countries. Further evidence is obtained as the utility of the newly proposed management plans should be evaluated in the Japanese population.
KW - Allergy
KW - Childhood asthma
KW - Clinical questions
KW - GRADE
KW - Guidelines
UR - http://www.scopus.com/inward/record.url?scp=85139375440&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139375440&partnerID=8YFLogxK
U2 - 10.1016/j.alit.2022.07.007
DO - 10.1016/j.alit.2022.07.007
M3 - Review article
C2 - 36085113
AN - SCOPUS:85139375440
SN - 1323-8930
VL - 71
SP - 472
EP - 480
JO - Allergology International
JF - Allergology International
IS - 4
ER -